HRP20212028T1 - Postupci za liječenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3 - Google Patents
Postupci za liječenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3 Download PDFInfo
- Publication number
- HRP20212028T1 HRP20212028T1 HRP20212028TT HRP20212028T HRP20212028T1 HR P20212028 T1 HRP20212028 T1 HR P20212028T1 HR P20212028T T HRP20212028T T HR P20212028TT HR P20212028 T HRP20212028 T HR P20212028T HR P20212028 T1 HRP20212028 T1 HR P20212028T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- amino acid
- acid sequence
- inhibitor
- angptl3
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 32
- 238000000034 method Methods 0.000 title claims 19
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 40
- 102100025668 Angiopoietin-related protein 3 Human genes 0.000 claims 23
- 101710085848 Angiopoietin-related protein 3 Proteins 0.000 claims 23
- 108700041144 Angiopoietin-Like Protein 8 Proteins 0.000 claims 22
- 102100034604 Angiopoietin-like protein 8 Human genes 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 208000030673 Homozygous familial hypercholesterolemia Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 201000005577 familial hyperlipidemia Diseases 0.000 claims 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010020606 Hyperchylomicronaemia Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229950004341 evinacumab Drugs 0.000 claims 1
- 201000011110 familial lipoprotein lipase deficiency Diseases 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 208000003532 hypothyroidism Diseases 0.000 claims 1
- 108091006086 inhibitor proteins Proteins 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662319980P | 2016-04-08 | 2016-04-08 | |
| US201762453110P | 2017-02-01 | 2017-02-01 | |
| PCT/US2017/026679 WO2017177181A1 (en) | 2016-04-08 | 2017-04-07 | Methods for treating hyperlipidemia with an angptl8 inhibitor and an angptl3 inhibitor |
| EP17719107.9A EP3439689B1 (en) | 2016-04-08 | 2017-04-07 | Methods for treating hyperlipidemia with an angptl8 inhibitor and an angptl3 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20212028T1 true HRP20212028T1 (hr) | 2022-04-01 |
Family
ID=58610026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20212028TT HRP20212028T1 (hr) | 2016-04-08 | 2017-04-07 | Postupci za liječenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20170291937A1 (OSRAM) |
| EP (1) | EP3439689B1 (OSRAM) |
| JP (1) | JP6964090B2 (OSRAM) |
| KR (1) | KR20180132843A (OSRAM) |
| CN (1) | CN109789194B (OSRAM) |
| AU (1) | AU2017248356A1 (OSRAM) |
| CA (1) | CA3020175A1 (OSRAM) |
| CY (1) | CY1124902T1 (OSRAM) |
| ES (1) | ES2896107T3 (OSRAM) |
| HR (1) | HRP20212028T1 (OSRAM) |
| HU (1) | HUE056878T2 (OSRAM) |
| IL (1) | IL262130A (OSRAM) |
| LT (1) | LT3439689T (OSRAM) |
| MD (1) | MD3439689T2 (OSRAM) |
| MX (1) | MX386832B (OSRAM) |
| PL (1) | PL3439689T3 (OSRAM) |
| PT (1) | PT3439689T (OSRAM) |
| RS (1) | RS62769B1 (OSRAM) |
| SI (1) | SI3439689T1 (OSRAM) |
| SM (1) | SMT202200016T1 (OSRAM) |
| WO (1) | WO2017177181A1 (OSRAM) |
| ZA (1) | ZA201806264B (OSRAM) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| MA43734A (fr) | 2016-03-03 | 2018-11-28 | Regeneron Pharma | Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3 |
| CN109069641A (zh) * | 2016-04-28 | 2018-12-21 | 瑞泽恩制药公司 | 用于治疗家族性高胆固醇血症患者的方法 |
| AU2017363143B2 (en) * | 2016-11-17 | 2022-07-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity with anti-ANGPTL8 antibodies |
| US10774139B2 (en) * | 2017-11-10 | 2020-09-15 | Ngm Biopharmaceuticals, Inc. | ANGPTL8-binding agents and methods of use thereof |
| WO2019126194A1 (en) | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Angptl8 assay and uses thereof |
| US12416004B2 (en) * | 2018-11-23 | 2025-09-16 | Sanofi | RNA compositions and methods for inhibiting ANGPTL8 |
| TWI747098B (zh) | 2018-12-21 | 2021-11-21 | 美商美國禮來大藥廠 | 抗angptl3/8複合物抗體及其使用方法 |
| CN112062844B (zh) * | 2019-06-10 | 2022-07-19 | 山东博安生物技术股份有限公司 | 抗angptl3抗体及其用途 |
| CN110596399B (zh) * | 2019-08-29 | 2022-07-22 | 首都医科大学附属北京安贞医院 | 检测血管生成素样蛋白8含量的物质的应用 |
| CN110613847B (zh) * | 2019-10-23 | 2022-02-11 | 北京市心肺血管疾病研究所 | 一种抑制血管生成素样蛋白8的物质的应用 |
| CN110694068A (zh) * | 2019-11-06 | 2020-01-17 | 北京市心肺血管疾病研究所 | 一种抑制血管生成素样蛋白8的物质的应用 |
| CN110694067A (zh) * | 2019-11-06 | 2020-01-17 | 首都医科大学附属北京安贞医院 | 一种抑制血管生成素样蛋白8的物质的应用 |
| CN110938144B (zh) * | 2019-11-27 | 2022-07-26 | 复旦大学附属儿科医院 | 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途 |
| CN111135303A (zh) * | 2020-01-17 | 2020-05-12 | 北京市心肺血管疾病研究所 | 一种抑制血管生成素样蛋白8的物质的应用 |
| BR112022014306A2 (pt) * | 2020-01-22 | 2022-09-20 | Jiangsu Hengrui Medicine Co | Anticorpo anti-angptl3 e uso do mesmo |
| JP2023538522A (ja) * | 2020-08-07 | 2023-09-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｎｇｐｔｌ３阻害剤を伴う難治性高コレステロール血症を処置するための方法 |
| CA3241896A1 (en) * | 2021-12-22 | 2023-06-29 | Regeneron Pharmaceuticals, Inc. | Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors |
| CN114671943B (zh) * | 2022-04-29 | 2023-05-05 | 四川大学 | 一种鱼类摄食调控蛋白的制备和应用 |
| CA3254156A1 (en) * | 2022-05-16 | 2023-11-23 | City Of Hope | Anti-CD84 antibodies and their uses |
| CN115947779B (zh) * | 2022-08-10 | 2025-04-25 | 武汉安砥生物科技有限公司 | 针对人血管生成素样蛋白3的免疫原性肽段及其载体疫苗和用途 |
| WO2024130165A1 (en) * | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome |
| WO2024227059A2 (en) * | 2023-04-27 | 2024-10-31 | Aligos Therapeutics, Inc. | Short interfering nucleic acid (sina) molecules targeting angptl 3 and angptl 8 and methods of using the same |
| CN117535353A (zh) * | 2023-10-11 | 2024-02-09 | 首都医科大学附属北京潞河医院 | 一种糖尿病视网膜病变模型的建立方法及应用 |
| CN119039435A (zh) * | 2024-09-21 | 2024-11-29 | 复旦大学附属儿科医院 | 一种抗angptl3人源化单抗及其应用 |
| CN119367545B (zh) * | 2025-01-02 | 2025-04-08 | 山东第一医科大学(山东省医学科学院) | 靶向干预ANGPTL8 mRNA在制备治疗高同型半胱氨酸血症药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| PL2374818T3 (pl) | 2006-06-02 | 2013-05-31 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| JP6680758B2 (ja) * | 2014-10-03 | 2020-04-15 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | 上昇したトリグリセリドと関連する状態の治療のための方法及び組成物 |
| TW201713690A (zh) * | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
-
2017
- 2017-04-07 MX MX2018012221A patent/MX386832B/es unknown
- 2017-04-07 HR HRP20212028TT patent/HRP20212028T1/hr unknown
- 2017-04-07 WO PCT/US2017/026679 patent/WO2017177181A1/en not_active Ceased
- 2017-04-07 PT PT177191079T patent/PT3439689T/pt unknown
- 2017-04-07 CN CN201780035121.1A patent/CN109789194B/zh not_active Expired - Fee Related
- 2017-04-07 SI SI201730953T patent/SI3439689T1/sl unknown
- 2017-04-07 US US15/482,499 patent/US20170291937A1/en not_active Abandoned
- 2017-04-07 JP JP2018552824A patent/JP6964090B2/ja active Active
- 2017-04-07 AU AU2017248356A patent/AU2017248356A1/en not_active Abandoned
- 2017-04-07 ES ES17719107T patent/ES2896107T3/es active Active
- 2017-04-07 LT LTEPPCT/US2017/026679T patent/LT3439689T/lt unknown
- 2017-04-07 PL PL17719107T patent/PL3439689T3/pl unknown
- 2017-04-07 HU HUE17719107A patent/HUE056878T2/hu unknown
- 2017-04-07 SM SM20220016T patent/SMT202200016T1/it unknown
- 2017-04-07 KR KR1020187032369A patent/KR20180132843A/ko not_active Abandoned
- 2017-04-07 EP EP17719107.9A patent/EP3439689B1/en active Active
- 2017-04-07 RS RS20211568A patent/RS62769B1/sr unknown
- 2017-04-07 CA CA3020175A patent/CA3020175A1/en active Pending
- 2017-04-07 MD MDE20190190T patent/MD3439689T2/ro not_active IP Right Cessation
-
2018
- 2018-09-18 ZA ZA2018/06264A patent/ZA201806264B/en unknown
- 2018-10-04 IL IL262130A patent/IL262130A/en unknown
-
2019
- 2019-11-15 US US16/685,876 patent/US20200377583A1/en not_active Abandoned
-
2022
- 2022-01-07 US US17/571,286 patent/US20220127348A1/en not_active Abandoned
- 2022-01-10 CY CY20221100023T patent/CY1124902T1/el unknown
-
2024
- 2024-08-12 US US18/801,099 patent/US20250066463A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200377583A1 (en) | 2020-12-03 |
| IL262130A (en) | 2018-11-29 |
| CN109789194A (zh) | 2019-05-21 |
| CY1124902T1 (el) | 2023-01-05 |
| LT3439689T (lt) | 2021-11-10 |
| PL3439689T3 (pl) | 2022-01-31 |
| ZA201806264B (en) | 2019-07-31 |
| CN109789194B (zh) | 2022-08-02 |
| HUE056878T2 (hu) | 2022-03-28 |
| SI3439689T1 (sl) | 2021-12-31 |
| ES2896107T3 (es) | 2022-02-23 |
| KR20180132843A (ko) | 2018-12-12 |
| EP3439689A1 (en) | 2019-02-13 |
| WO2017177181A1 (en) | 2017-10-12 |
| MD3439689T2 (ro) | 2021-12-31 |
| MX2018012221A (es) | 2019-02-13 |
| US20250066463A1 (en) | 2025-02-27 |
| JP2019513751A (ja) | 2019-05-30 |
| JP6964090B2 (ja) | 2021-11-10 |
| PT3439689T (pt) | 2021-11-04 |
| SMT202200016T1 (it) | 2022-03-21 |
| US20170291937A1 (en) | 2017-10-12 |
| EP3439689B1 (en) | 2021-10-13 |
| CA3020175A1 (en) | 2017-10-12 |
| AU2017248356A1 (en) | 2018-10-25 |
| US20220127348A1 (en) | 2022-04-28 |
| RS62769B1 (sr) | 2022-01-31 |
| MX386832B (es) | 2025-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20212028T1 (hr) | Postupci za liječenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3 | |
| JP2019513751A5 (OSRAM) | ||
| JP2019531273A5 (OSRAM) | ||
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| IL261019A (en) | Antibodies to 6 -il and their use | |
| JP2015526440A5 (OSRAM) | ||
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| CY1115456T1 (el) | Μεθοδος χορηγησης αντισωματων αντι-ιl-5 | |
| RU2012156938A (ru) | Антитела против gdf8 человека | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| RU2015130100A (ru) | TNF-альфа антиген-связывающие белки | |
| AR081434A1 (es) | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo | |
| HRP20200882T1 (hr) | Vezujuće molekule specifične za asct2 i njihova uporaba | |
| IL273678B2 (en) | Methods for treating allergy and improving allergen-specific immunotherapy by administering an IL-4R inhibitor | |
| PE20160999A1 (es) | Metodos para administrar anticuerpos anti-tnf-alfa | |
| HRP20201656T1 (hr) | Neutralizacija inhibitornih putova u limfocitima | |
| RU2009110102A (ru) | Лечение опухолей с помощью антитела к vegf | |
| JP2011506483A5 (OSRAM) | ||
| RU2017120358A (ru) | Анти-il-1-бета антитела и способы их применения | |
| HRP20230992T1 (hr) | Postupci za liječenje ili sprečavanje ateroskleroze davanjem inhibitora angptl3 | |
| CN111788230B (zh) | 抗TrkA抗体 | |
| JP2019512472A5 (OSRAM) | ||
| JP2016094424A5 (OSRAM) | ||
| RU2018100824A (ru) | Антитела, которые связываются с сортилином и подавляют связывание програнулина | |
| HRP20241795T1 (hr) | Anti-adrenomedulin (adm) – vezujući entitet za uporabu u terapiji ili prevenciji simptoma bolesti |